RT Journal Article
SR Electronic
T1 A Case of Hydroxyurea-induced Leg Ulcer after Definitive Treatment Suspension in a Patient Affected by Thrombocythemia: Effectiveness of a New Collagenase
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 1053
OP 1056
VO 26
IS 6
A1 FIORAMONTI, PAOLO
A1 FINO, PASQUALE
A1 PARISI, PAOLA
A1 SCUDERI, NICOLO
A1 ONESTI, MARIA G.
YR 2012
UL http://iv.iiarjournals.org/content/26/6/1053.abstract
AB Hydroxyurea (HU) is an antitumor agent effective in the treatment of myeloproliferative disorders. It is usually well-tolerated and has low toxicity but its use is associated with several adverse cutaneous effects. Among them, leg ulcers have been noted in association with long-term administration. Poor response to traditional local and systemic therapy is a typical feature of HU-induced leg ulcers, and discontinuation of the drug is often required to achieve complete wound healing. We present a case of circumferential HU-induced leg ulcer in a patient affected by essential thrombocythemia, in which the lesion occured after the definitive suspension of the treatment. We propose a conservative management with a new collagenase (Bionect Start®) for skin lesions in this type of patient, for whom a surgical treatment could be more complicated, due to the underlying disease.